Trials
3 active
14 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Psoriatic Arthritis, Vitiligo, Non-segmental Vitiligo
- Main trialPhase 3
- “This study is a phase 3 study,to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with active psoriatic arthritis.”In the company’s words, NCT04957550 on ClinicalTrials.gov
Other drugs for Psoriatic Arthritis
- SonelokimabMoonLake Immunotherapeutics AG · Phase 3
- IcotrokinraJohnson & Johnson (Janssen) · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- ZasocitinibTakeda · Phase 3
- UstekinumabJohnson & Johnson (Janssen) · Phase 3
- TildrakizumabSun Pharma · Phase 3
Coming up2
- 13 DecPhase 3 trial completes · ClinicalTrials.gov
- Mar 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials14
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 13 Dec 2026 | To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis | |
| Phase 2Active, not recruiting | 3 Mar 2026 | A Trial of SHR0302Base in Patients With Vitiligo | |
| Phase 2Recruiting | Mar 2027 | A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo | |
| Phase 3Completed | 30 Jan 2023 | A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis | |
| Phase 3Unknown | 30 Aug 2024 | A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Non-Radiographic Axial Spondyloarthritis | |
| Phase 2/3Completed | 15 Nov 2022 | A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Ankylosing Spondylitis | |
| Phase 2Completed | 16 Apr 2019 | Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) Patients | |
| Phase 1Completed | 27 Dec 2020 | Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment | |
| Phase 1Completed | 13 Apr 2021 | Study on the Bioavailability of SHR0302 in Healthy Subjects | |
| Phase 1Completed | 19 Sep 2021 | A Study of Human Substance Balance and Biotransformation of [14C]SHR0302 | |
| Phase 1Completed | 18 Aug 2022 | A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers | |
| Phase 1Completed | 3 Jul 2023 | To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability | |
| Phase 1Completed | 21 Feb 2024 | A SHR0302 BA Study on Healthy Subjects | |
| Phase 1Completed | 31 Jul 2024 | A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Pharmacokinetic Profile of Single and Multiple Dose Escalation Topical Dermal Administration of SHR0302 Alkali Gel in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026